PDF hosted at the Radboud Repository of the Radboud University Nijmegen

The following full text is a publisher's version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/23398

Please be advised that this information was generated on 2017-11-27 and may be subject to change.
Autoantibodies to myeloperoxidase (MPO) are present in sera from patients with various forms of vasculitis-associated glomerulonephritis. Evidence for a pathogenic role of anti-MPO antibodies has been provided mainly by in vitro studies. We studied the pathogenic role of autoantibodies to MPO in a rat model of mild immune-mediated glomerular injury. Brown Norway rats were immunized with human MPO in complete Freund's adjuvant or with complete Freund's adjuvant alone. At 2 weeks after immunization, rats had developed antibodies to human and rat MPO as detected by indirect immunofluorescence, enzyme-linked immunosorbent assay, and immunoprecipitation. At this time point, rats were intravenously injected with a subnephritogenic dose of 150 μg of rabbit anti-rat GBM. Rats were sacrificed at 4 hours, 24 hours, 4 days, and 10 days after antibody administration. Control immunized rats developed mild glomerulonephritis characterized by slight proteinuria at day 10 (14.8 ± 8.1 mg/24 hours) and moderate intraglomerular accumulation of EDI+ macrophages. Crescent formation, tuft necrosis, and tubular atrophy were not observed in those rats. In contrast, rats immunized with MPO developed severe glomerulonephritis characterized by the early occurrence of severe hematuria, marked proteinuria at day 10 (76.2 ± 18.2 mg/24 hours), and massive glomerular deposition of fibrin. Complement and rat IgG were present in insudative lesions, but no linear pattern along the glomerular capillary wall was observed. By light microscopy, severe glomerular lesions were found at day 10 consisting of crescent formation and fibrinoid necrosis of capillary loops. In the interstitium, tubular necrosis and atrophy and marked interstitial mononuclear infiltration were found. In conclusion, autoantibodies to MPO severely aggravate subclinical anti-GBM disease demonstrating their in vivo pathogenic potential. (Am J Pathol 1996, 149:1695-1706)
to monolayers of cultured endothelial cells and that primed neutrophils in the presence of ANCA-induced lysis of endothelial cells. So far, the in vivo relevance of these phenomena is not clear.

In a recent study, we hypothesized that NCGN may develop after focal degranulation and production of H$_2$O$_2$ by activated polymorphonuclear leukocytes (PMNs) in the presence of anti-MPO antibodies. This hypothesis was tested by perfusion of a human lysosomal enzyme extract and H$_2$O$_2$ into the kidney of Brown Norway rats previously immunized with human (h)MPO. These rats were found to develop a proliferative NCGN closely resembling human NCGN. The relevance of this animal model for human disease is, however, hampered by its use of heterologous MPO and the necessity to perfuse the kidneys. In the present study, we evaluated whether a MPO-directed autoimmune response in Brown Norway rats is able to aggravate subclinical anti-GBM disease. These studies would provide more evidence for the pathogenic potential of anti-MPO antibodies in this and perhaps other types of immune-mediated renal diseases.

**Materials and Methods**

**Animals**

All experiments were performed in conventionally housed, 3-month-old Brown Norway rats (Harlan, Bilthoven, The Netherlands). Animals were fed ad libitum with standard chow (Hope Farms, Woerden, The Netherlands).

**Isolation of Human Myeloperoxidase**

hMPO was isolated as described before. Briefly, isolated human PMNs were dissolved in cetylmethyl ammonium chloride (Sigma Chemical Co., St. Louis, MO) and sonicated. The extract was absorbed to a concanavalin A Sepharose gel (Pharmacia, Uppsala, Sweden) and eluted with methyl-D-mannoside (Sigma). The eluate was further purified on a Sephadex G100 gel (Pharmacia). The final hMPO preparation had an optical density (OD) 428/280 ratio of 0.85, measured as the ratio between the OD at 428 nm (showing a specific spectral band for MPO) and the OD obtained at 280 nm. The preparation was not contaminated with proteinase 3, elastase, or lactoferrin as estimated by antigen-specific enzyme-linked immunosorbent assay (ELISA), and analysis by gel electrophoresis showed specific bands for hMPO (at 15, 38, and 58 kd; data not shown).

**Isolation of Rat Myeloperoxidase**

Rat MPO was purified from peritoneal exudate cells (PECs). These PEC suspensions were obtained from the peritoneal cavity of Brown Norway rats 16 hours after an intraperitoneal injection of 7 ml of saline with 10% protease peptone (Difco, Detroit, MI) and 0.6% heart infusion broth. Cell suspensions were harvested by washing the peritoneal cavity with phosphate-buffered saline (PBS) and contained more than 90% PMNs as judged by morphological criteria. Rat MPO was purified from the PEC suspension as described for hMPO.

**Immunization**

Brown Norway rats were immunized with hMPO in complete Freund's adjuvant supplemented with 5 mg/ml H37RA (Difco). Rats received 10 µg of hMPO or control solution (sodium acetate buffer) without hMPO subcutaneously in 0.2 ml at two sites near the base of the tail.

**Detection of Anti-Human MPO and Anti-Rat MPO Antibodies by ELISA**

Microtiter plates (Greiner, Kremsmunster, Austria) were coated for 2 hours at 37°C with hMPO or rat MPO at a protein concentration of 2 µg/ml in 0.1 mol/L carbonate buffer, pH 9.6. Plates were incubated with rat serum, diluted in 0.05 mol/L Tris/HCl, 0.05% Tween-20, 1% normal goat serum, 2% bovine serum albumin, and 0.3 mol/L NaCl, pH 8.0, starting at a dilution of 1:100 for hMPO and 1:25 for rat MPO. Antibody binding was detected with alkaline-phosphatase-labeled goat anti-rat Ig (Cappel Laboratories, West Chester, PA) followed by p-nitrophenyl phosphate disodium as a substrate. The plates were read at 405 nm, and a standard curve was prepared from a reference serum. Antibody titers were computed from the linearized titration curve of the reference serum. The antibody titer of the reference serum was set at 100 U.

**Detection of Anti-Human MPO and Anti-Rat MPO Antibodies by Immunofluorescence**

Antibodies to hMPO and rat MPO were detected by indirect immunofluorescence on ethanol-fixed human granulocytes or cytospin preparations of rat PECs. Rat plasma was diluted 1:10, and fluorescein isothiocyanate (FITC)-labeled rabbit anti-rat IgG (Cappel) was used to detect bound antibodies.
Detection of Anti-Rat MPO Antibodies by Immunoprecipitation

PECs were obtained as described above. A crude extract was prepared by nitrogen cavitation and urea extraction in the presence of protease inhibitors. Nuclei and membrane fragments were discarded by centrifugation. The antigens were labeled with [125I] by the iodogen method and diluted in PBS containing 4% bovine serum albumin, 1% Triton X-100, 0.5% sodium dodecyl sulfate, and 0.5 mol/L NaCl (immunoprecipitation buffer). Antibody-bound antigen complexes were precipitated with protein A CL-4B (Pharmacia), 5 mg per plasma sample, washed with Immunoprecipitation buffer, PBS, and 10 mmol/L Tris/HCl, pH 6.8, and centrifuged through a sucrose gradient. The samples were boiled for 1 minute in β-mercaptoethanol/SDS and run on a 12.5% SDS-polyacrylamide gel. After electrophoresis, gels were vacuum dried and exposed to a Kodak XAR5 film.

Induction of Anti-GBM Nephritis

Antiserum against rat GBM was raised in rabbits as follows. Rat glomeruli were purified from renal cortex tissue by a sieving technique.20 Subsequently, GBMs were isolated from the glomeruli by the detergent method.21 Rabbits were immunized with 1 mg of rat GBM in complete Freund’s adjuvant by multiple subcutaneous injections and boosted at 1-month intervals with 1 mg of rat GBM in incomplete Freund’s adjuvant. Antibody titers were controlled by immunofluorescence. IgG was purified from serum by ammonium sulfate precipitation followed by protein A Sepharose affinity chromatography. At 2 weeks after immunization with hMPO, rats received a subnephrotic dose of 150 µg of anti-GBM antibodies intravenously in 1 ml of PBS. Radiolabel experiments showed that equal amounts of rabbit IgG bound in the kidney of MPO-immunized and control immunized rats (2.9 ± 0.6 µg/g of kidney (n = 3) versus 3.0 ± 0.4 µg/g of kidney (n = 3)). For estimation of proteinuria and hematuria, urine was collected in metabolic cages during 24 hours after the anti-GBM injection and before the day of sacrifice at 4 and 10 days. The protein content was measured with the biuret method. Hematuria was evaluated with the XAR5 film.

Histopathology

At the times indicated, kidneys were perfused with PBS at 4°C to remove the blood. Tissue samples from the left and right kidney were obtained and prepared for light microscopy, immunofluorescence, and immunohistochemistry. For light microscopy, renal tissue was fixed in 2% paraformaldehyde/PBS and embedded in glycomethacrylate (Technovit 8100 solution, Kulzer, Wehrheim, Germany) as described.22 The 2-µm sections were cut and stained with periodic acid-Schiff and periodic acid silver methamine. The percentage of crescentic glomeruli was estimated by examination of 50 glomeruli on periodic acid-Schiff-stained plastic sections and counting the number of crescentic glomeruli. For immunofluorescence, tissue samples were snap frozen in isopentane. The 4-µm sections were fixed in acetone and then preincubated with normal serum from the same species as the conjugate. Detection of rabbit IgG, rat IgG, complement, and fibrin was tested with fluorescein isothiocyanate (FITC)-labeled F(ab)2 goat anti-rabbit IgG, F(ab)2 goat anti-rat IgG, FITC-labeled F(ab)2 goat anti-rat C3, and goat anti-rat fibrinogen (all from Cappel). As a conjugate, FITC-labeled F(ab)2 rabbit anti-goat was used (Cappel). The amount of rabbit IgG, rat IgG, and complement was scored on a semiquantitative scale as follows: 0, absent; 1, weak; 2, mild; 3, intermediate; 4, strong. Fibrin deposition was evaluated by scoring the extent of fibrin deposition in 50 glomeruli per rat according to the following scale: 0, absent; 1, less than 25%; 2, between 25 and 50%; 3, between 50 and 75%, and 4, between 75 and 100% of the total glomerular area. The fibrin score per rat was expressed as the sum of the individual glomerular scores.

PMNs, monocytes, and T cells were detected by immunoperoxidase staining using the monoclonal antibodies His48 (PMNs23,24), ED1 (monocytes; Serotec, Oxford, UK), and R73 (T cells25), followed by peroxidase-labeled rabbit anti-mouse (Dakopatts, Glostrup, Denmark) and aminoethylcarbazole as a substrate. Endogenous peroxidase activity was blocked with 0.05% H2O2 in PBS. Sections were counterstained with hematoxylin. Glomerular infiltrates were estimated by scoring the number of His48-, ED1-, and R73-positive cells within 50 glomeruli and dividing the total by 50. Intersitial inflam-
trates were quantified on a semiquantitative scale: 0, absent; 1, minimal; 2, mild; 3, moderate; 4, severe.

**Glomerular Presence of Rat MPO**

The presence of rat MPO was studied on plastic-embedded sections for optimal morphological detail. Dried 2-μm sections were fixed with acetone-buffered formalin (9%) according to Pryzwansky to prevent artifactual shifting of highly cationic MPO. To study the possible extracellular localization of rat MPO we applied double-labeling immunofluorescence using CD11b as a leukocyte marker. For this purpose, sections were preincubated with 10% goat serum, followed by a mixture of mouse anti-rat CD11b (OX 42) and biotinylated rabbit anti-rat MPO for 2 hours at 37°C. This was followed by incubation with a mixture of tetraethylrhodamine-isothiocyanatelabeled goat anti-mouse IgG (Southern Biotechnology Associates, Birmingham, AL) and FITC-labeled streptavidin (Dakopatts) supplemented with 1% normal rat serum. Sections were mounted in Citifluor (Fenwall Laboratories, London, UK). Controls included the omission of biotinylated rabbit anti-rat MPO or OX 42 or both and incubating biotinylated rabbit anti-rat MPO or OX 42 with the second step used for the other antibody in the double staining.

**Statistical Analysis**

Values were expressed as mean ± SD and were analyzed for statistical differences by the two-tailed Mann-Whitney U test. Probability values of <0.05 were considered significant.

**Experimental Design**

Two experimental groups were formed. In the first group, hMPO-immunized rats received an injection of a subnephritogenic dose of rabbit anti-rat GBM. Rats were sacrificed at 4 hours (n = 3), 24 hours (n = 4), 4 days (n = 5), and 10 days (n = 5). In the second group, control immunized rats received an injection of a subnephritogenic dose of rabbit anti-rat GBM. Rats were sacrificed at 4 hours (n = 4), 24 hours (n = 5), 4 days (n = 4), and 10 days (n = 4).

**Results**

**Immune Response to Human and Rat MPO**

Brown Norway rats immunized with hMPO developed antibodies reacting with human and rat MPO as detected by indirect immunofluorescence (Figure 1) and ELISA (Figure 2). The antibodies specifically precipitated rat MPO from a crude extract prepared from rat PECs (Figure 3). The same bands were precipitated by a polyclonal antibody raised against purified rat MPO that, in addition, recognizes smaller MPO fragments. Sera from control immunized rats were negative in all tests.

**Urine Analysis**

Control immunized rats receiving rabbit anti-GBM antibodies developed moderate hematuria 10 days after injection (Figure 4). At earlier time points, only intermediate hematuria was found in some rats, the majority being negative. In contrast, intermediate to severe hematuria developed in hMPO-immunized animals starting at 24 hours after the anti-GBM antibody administration. Hematuria increased in severity during the time period of the experiment (Figure 4). Urine samples from rats at day 10 still showed maximal hematuria after 10-fold dilution in physiological saline, illustrating the extent of hematuria. In addition, low-grade proteinuria was detectable 4 days after anti-GBM antibody administration in both groups and had increased at day 10 with a significantly higher degree of proteinuria in hMPO-immunized rats as compared with control rats (76.2 ± 18.2 mg/24 hours versus 14.8 ± 8.1 mg/24 hours; Figure 5).
Autoantibodies to Myeloperoxidase Aggravate Glomerular Injury

Histopathology

Macrosopic Appearance of Kidneys

The macrosopic appearance of kidneys from control immunized rats showed no abnormalities except for occasional petechiae 10 days after the administration of anti-GBM antibodies (Figure 6). However, kidneys from hMPO-immunized animals showed some petechiae at 4 hours and widespread petechiae at 24 hours and 4 and 10 days. In addition, kidneys at 10 days were swollen and had a pale appearance (Figure 6).

Light Microscopy

In hMPO-immunized rats, a moderate influx of PMNs was found at 4 hours. At 24 hours, a local influx of PMNs and monocytes was observed in the glomeruli of hMPO-immunized rats. In addition, in some glomeruli capillaries showed thrombosis with hemostasis and swelling of endothelial cells (Figure 7A). These changes were less conspicuous in the control immunized rats. At 4 days, the rats from the hMPO-immunized group showed increased numbers of intracapillary cells, mostly macrophages with endothelial and mesangial proliferation and segmental proliferation of epithelial cells in Bowman’s space. At 10 days, the hMPO-immunized rats showed exten-
Intracapillary proliferation with fibrinoid necrosis of capillary walls, extravasation of erythrocytes, and in some glomeruli destruction of Bowman's capsule with formation of multinucleated giant cells. Crescent formation was found in 24 to 60% of the glomeruli (mean, 41.2%; n = 5). In most kidneys, extensive interstitial inflammatory changes were observed at this time (Figure 7, D–F). At 10 days after anti-GBM IgG administration, the kidneys of control immunized rats showed only mild intracapillary proliferation as shown in Figure 7B. Severe lesions, such as the development of crescents, the occurrence of interstitial infiltrates and tubular atrophy, and necrosis were not observed.

**Immunophenotyping**

Phenotypic analysis of intraglomerular inflammatory cells in control immunized rats showed a slight influx of PMNs (1.3 ± 0.3 per glomerulus) at 4 hours after anti-GBM administration (see Table 2). At later time points, the predominant infiltrating cells were ED1+ macrophages, which peaked at day 4. No intraglomerular T cells were found at any time (Table 1). In addition, interstitial macrophages were only occasionally found at day 10 (Table 1). Rats immunized with hMPO also showed an influx of PMNs (1.9 ± 0.4 per glomerulus) at 4 hours and ED1+ macrophages at 24 hours and 4 and 10 days after anti-GBM administration (Table 1). The total number of infiltrating inflammatory cells was generally higher compared with control immunized rats. Occasionally, some T cells were observed at day 10 (Table 1). In addition, at 10 days, large numbers of inflammatory cells accumulated in the interstitium mainly consisting of ED1+ macrophages (Table 1).

**Immunofluorescence**

Immunofluorescence studies showed strong linear deposition of rabbit IgG along the glomerular capillary wall at all time points in both experimental groups (Figure 8 and Table 2). Complement C3 was only weakly present whereas no linear deposition of rat IgG was found along the capillary walls of either
group at any time (Figure 8). However, complement and rat IgG were detected in Bowman's space in conjunction with fibrinoid necrosis and cellular crescents at day 10 in hMPO-immunized rats (Figure 8). Until day 4, deposition of fibrin showed a similar pattern and extent in both groups. No deposition of fibrin was found at 4 hours whereas weak diffuse deposition was seen at 24 hours (Figure 9). At day 4, 30 to 50% of the glomeruli showed focal and segmental glomerular deposition of fibrin. At 10 days after anti-GBM administration, a significant difference in glomerular fibrin score was found between both experimental groups (Figure 9). In hMPO-immunized rats, fibrin deposition had increased in intensity, involving most glomeruli. At this time, fibrin deposition was also found in Bowman's space, within crescents, and in tubular lumens (Figures 8 and 9). In contrast, the pattern and extent of fibrin deposition in control immunized rats was not significantly different from that found at day 4 (Figure 9).

Glomerular Presence of Rat MPO

Staining for rat MPO showed strong intracellular staining of infiltrating leukocytes at 4 and 24 hours after anti-GBM administration in both groups (Figure 10A). In addition, extracellular granular staining of rat MPO was observed (Figure 10, B and C), although not all rat-MPO-positive cells were accompanied by extracellular staining. No apparent difference in the amount of extracellular staining was noted between hMPO-immunized and control immunized rats. At 4 and 10 days after anti-GBM administration, only weak staining for rat MPO was found in both groups.

Discussion

In the present study, rats immunized with hMPO developed antibodies to hMPO that cross-reacted with rat MPO. When, subsequently, these rats were challenged with a subnephritogenic dose of rabbit anti-rat GBM antibodies, severe glomerulonephritis developed. Clinically, the glomerulonephritis was characterized by the early onset of severe hematuria and exacerbation of proteinuria while histopathologically crescent formation, tuft necrosis, and tubulointerstitial nephritis were observed. In contrast, control immunized rats receiving the same amount of rabbit anti-rat GBM antibodies showed only mild glomerulonephritis. These results demonstrate a pathogenic role of the anti-rat MPO autoantibodies in the development of crescentic glomerulonephritis in this experimental model.

Several other in vivo observations have pointed toward a pathogenic role for ANCAs. Anti-MPO antibodies have been demonstrated in sera from mercury-chloride-treated Brown Norway rats and in a mouse strain with spontaneous NCgN developed by genetic selection from lupus prone MRL mice.59,70 Interestingly, in both models, vasculitis has been observed. However, the immune response to MPO is part of a polyclonal B-cell stimulation in both models, which makes the specific pathophysiological role of anti-MPO antibodies in the induction of vasculitis difficult to interpret. The studies presented here are based on the hypothesis that focal neutrophil activation by circulating autoantibodies to MPO leads to the development of anti-MPO-associated crescentic glomerulonephritis. As has been reported previ-

<table>
<thead>
<tr>
<th>Infiltrating cells</th>
<th>Groups</th>
<th>4 hours</th>
<th>24 hours</th>
<th>4 days</th>
<th>10 days</th>
<th>4 hours</th>
<th>24 hours</th>
<th>4 days</th>
<th>10 days</th>
</tr>
</thead>
<tbody>
<tr>
<td>PMNs</td>
<td>I</td>
<td>1.9 ± 0.4</td>
<td>1.4 ± 0.4</td>
<td>0.78 ± 0.1</td>
<td>1.2 ± 0.2</td>
<td>0</td>
<td>0.8 ± 0.4</td>
<td>2.2 ± 0.4</td>
<td></td>
</tr>
<tr>
<td></td>
<td>II</td>
<td>1.3 ± 0.3</td>
<td>1.0 ± 0.3</td>
<td>0.72 ± 0.3</td>
<td>0.7 ± 0.1</td>
<td>0</td>
<td>1.4 ± 0.2</td>
<td>3.2 ± 0.2</td>
<td></td>
</tr>
<tr>
<td>Monocytes</td>
<td>I</td>
<td>1.1 ± 0.1</td>
<td>2.7 ± 0.7</td>
<td>7.0 ± 1.6</td>
<td>5.9 ± 1.5</td>
<td>0</td>
<td>0.3 ± 0.3</td>
<td>5.0 ± 0.3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>II</td>
<td>0.7 ± 0.1</td>
<td>2.5 ± 1.3</td>
<td>6.0 ± 2.7</td>
<td>3.7 ± 0.5</td>
<td>0</td>
<td>0.3 ± 0.3</td>
<td>5.0 ± 0.3</td>
<td></td>
</tr>
<tr>
<td>T cells</td>
<td>I</td>
<td>0</td>
<td>0</td>
<td>0.2 ± 0.1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>II</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

In group I, rats were immunized with hMPO, in group II were control immunized rats. The number of intraglomerular PMNs, monocytes, and T cells after estimated by counting positive cells in 50 glomeruli and dividing the total by 50. Numbers represent mean ± SD. Labeled interstitial cells were scored on a semiquantitative scale: 0, absent; 1, minimal; 2, mild; 3, moderate; 4, severe. Results represent mean scores ± SEM.

*P < 0.05.
Intraglomerular Presence of Rabbit IgG, rat IgG, and Complement

<table>
<thead>
<tr>
<th>Groups</th>
<th>Rabbit IgG</th>
<th>Rat IgG</th>
<th>Complement</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>4 hours</td>
<td>24 hours</td>
<td>4 days</td>
</tr>
<tr>
<td>I</td>
<td>4</td>
<td>4</td>
<td>3.6 ± 0.2</td>
</tr>
<tr>
<td>II</td>
<td>4</td>
<td>4</td>
<td>1.3 ± 0.3</td>
</tr>
</tbody>
</table>

In group I, rats were immunized with hMPO. In group II were control immunized rats. The presence of rabbit IgG, rat IgG, and complement was scored on a semiquantitative scale: 0, absent; 1, weak; 2, mild; 3, intermediate; 4, strong. Results represent mean scores ± SEM.

Intraglomerular presence of complement, the development of anti-MPO antibodies after immunization is in itself not sufficient to induce any lesions. In addition, in vitro studies have shown that ANCAs stimulate human PMNs to produce reactive oxygen metabolites and enhance degranulation only after cytokine priming of PMNs. In our model, the induction of a mild anti-GBM nephritis possibly served as the priming process. Administration of a subnephritogenic dose of anti-GBM results in a mild PMN influx and complement activation. In the presence of MPO autoantibodies, this may result in the development of severe NCGN. The exact mechanisms by which the autoantibodies to MPO aggravate mild anti-GBM nephritis are not clear, but several possibilities may be considered.

First, in vitro studies have shown that anti-GBM/GBM immune complexes as well as anti-MPO antibodies can induce MPO release from PMNs, and both mechanisms may be relevant in the model presented here. Indeed, rat MPO was found in an extracellular localization in glomerular capillary structures. MPO is a highly cationic enzyme that, upon exocytosis or degranulation, will bind to negatively charged structures such as the GBM or endothelial cells. Active MPO reacts with H₂O₂ and halides to form reactive oxygen metabolites that induce acute glomerular injury. Once MPO is released from the cell, MPO/anti-MPO complexes may form, leading to prolonged presence of the active enzyme and more extensive morphological damage.

Second, the development of focal MPO/anti-MPO immune complexes may also enhance the influx of inflammatory cells resulting in an increased production of reactive oxygen radicals and release of pro-

Figure 9. Glomerular fibrin deposition at 24 hours and 4 and 10 days after anti-GBM administration to control and hMPO-immunized rats. Fibrin deposition was scored semiquantitatively according to the following scale: 0, absent; 1, less than 25%; 2, between 25 and 50%; 3, between 50 and 75%; and 4, between 75 and 100% of the total glomerular area. Results are expressed as mean score ± SD. *P < 0.02.

Figure 10. Localization of rat MPO in glomeruli from hMPO-immunized rats 24 hours after anti-GBM administration by indirect immunofluorescence. A: Intracellular localization of rat MPO. B: Intracellular staining accompanied by extracellular granular staining of rat MPO. C: Extracellular staining of rat MPO (arrow). Magnification × 800.
teolytic enzymes. However, it should be stressed that we found no abnormal quantities of rat IgG in the glomeruli. The role of focal immune complex formation in anti-MPO-associated NCGN was also tested by Brouwer et al. They developed an animal model in which a human neutrophil lysosomal extract consisting of MPO and trace amounts of proteinase 3 and elastase and H$_2$O$_2$ were perfused into the kidney of Brown Norway rats previously immunized with hMPO. These rats developed a NCGN characterized by intra- and extracapillary proliferation, ruptured Bowman's capsule, periglomerular granulomatous inflammation, and formation of giant cells while IgG and C3 were scanty or absent. This model therefore closely resembles the human disease of ANCA-associated NCGN, although some controversy exists on the pauci-immune character of this model. In line with these observations are the data of Kobayashi et al., who described exacerbation of anti-GBM disease in the rat by heterologous anti-rat MPO antibodies. They showed that the administration of rabbit anti-rat MPO together with anti-GBM antibodies increases fibrin accumulation and the number of infiltrating PMNs 3 and 15 hours after injection, although neither crescent formation or tuft necrosis was seen. In addition, deposition of rat MPO along the GBM was found, and anti-MPO antibodies could be eluted from the kidney. These results suggest that focal MPO/anti-MPO immune complex formation is responsible for the aggravation of the anti-GBM nephritis. However, this model is based on heterologous anti-MPO antibodies and therefore cannot be regarded as a genuine autoimmune model for ANCA-associated glomerulonephritis.

Third, recent studies have shown that anti-MPO antibodies enhance cytokine production by PMNs. Cytokines, like tumor necrosis factor-α and interleukin-1, aggravate mild anti-GBM nephritis when administered systemically. In addition, it was shown that, in patients with active Wegener's disease as well as in sepsis patients, monocytes express MPO on their cell surface, and it has been reported that ANCAs induce monocyte chemoattractant protein-1 production by monocytes. Therefore, increased cytokine production by monocytes and PMNs due to interaction with anti-MPO antibodies could be an alternative mechanism in our model and should be studied further.

In conclusion, these studies demonstrate that autoantibodies to MPO markedly aggravate mild anti-GBM disease and suggest that ANCAs may be a pathogenic factor in rendering mild glomerular injury into clinically overt disease.

References


14. Vargunam M, Actu D, Taylor CM, Michael J, Richards N,


